Gilead puts its Car-T money where its mouth is
KITE-753 is to enter pivotal development – head-to-head against Yescarta.
Henlius starts a pivotal journey to catch Pfizer
The Chinese company will start the first of four pivotal trials of its PD-L1 ADC in April.
Regeneron has a new multiple myeloma hope
The company reveals its anti-GPRC5D T-cell engager.
J&J sidelines a novel project
The company’s TRPV1 antagonist looks doomed.
CCR8 promise and peril
Pivotal trials and novel combinations have started, but four programmes seem to have been discontinued.
A new challenger in target degradation
Ascentage hopes to become a new force in BTK.
AbbVie and RemeGen’s bispecific goes pivotal
Chinese trials in first-line NSCLC and colorectal cancer are imminent.
Akeso casts doubts on CD73 efforts
The company has ditched a trial of drebuxelimab plus ivonescimab.
Betta joins Revolution in pan-RAS inhibition
BPI-572270 enters clinical trials.
